CSF2 and cancer: Recently, biomaterial-based vaccination systems encapsulating GM-CSF, TLR agonists (e.g., CpG) and autologous irradiated cancer cells alone or in combination with immune checkpoint inhibitors have shown promising results in experimental cancer models [124,125,126,127,128].